Dr. Neil Vasdev

Dr. Vasdev received Bachelor’s degrees (summa cum laude, Hon. B.Sc. Chemistry & B.A. Psychology), followed by a Ph.D. (chemistry) from McMaster University. Prior to starting graduate school he worked in industry as a chemist at Astra Pharma and GlaxoWellcome, as well as at a radiopharmacy. Following a postdoctoral fellowship in radiochemistry at Berkeley National Labs, he joined the faculty at the University of Toronto (2004-2011). He was the Director of Radiochemistry at Massachusetts General Hospital (2011-2017), and maintains a faculty appointment at Harvard Medical School.

He recently returned to Canada as the inaugural Director of the AzrieliCentre for Neuro-Radiochemistry, at CAMH. He serves as the Associate Director and Chief Radiochemist of the CAMH Research Imaging Centre. He is also the endowed AzrieliChair in Brain and Behaviour, and a Tier 1 Canada Research Chair in Radiochemistry and Nuclear Medicine. In addition, he is a full Professor in the Department of Psychiatry at the University of Toronto.

Radiotracers developed by the Vasdev laboratory are in preclinical use worldwide, and many selected for first-in-human neuroimaging studies. Dr. Vasdev has published more than 100 peer-reviewed articles, and he has received numerous scholarly awards throughout his career.

MCI_Headshots_©HOGGER&Co._web_009.jpg

Dr. Lee Josephson

Dr. Josephson received a B.S. from the University of Wisconsin (Chemistry) and a Ph.D. from Stony Brook University (Chemical Biology). He then did a post-doctoral fellowship at Harvard University under Dr. Guido Guidottiand was a cofounder of AMAG Pharmaceuticals (AMAG, AMEX). There he served as Chief Scientific Officer and lead the development of FDA approved magnetic nanoparticle MR contrast agents.

He joined the Massachusetts General Hospital in 1997 and was a Co-founder of T2 Biosystems (TTOO, NASDAQ).

Dr. Josephson’s research interests include the design of radioactive, magnetic and fluorescent imaging probes and the use of magnetic nanoparticles for in vitro clinical assays.

He has published over 100 peer-reviewed papers and is a co-inventor on more than 35 issued US patents. He is an Associate Professor in the Department of Radiology at Harvard Medical School.

MCI_Headshots_©HOGGER&Co._website_017.jpg

Dr. Jack Hoppin

Dr. Hoppin is a Co-founder and the Managing Director of inviCRO, a Konica-Minolta company. Invicro was founded with a mission of improving the role and function of imaging in drug discovery and development, by offering clients a wide range of services and software. These range from analyses of sectioned tissues to analyses of pre-clinical and clinical images with a wide range of modalities (e.g. PET, SPECT, MRI, fluorescence). Invicro employs more than 200 research scientists representing a broad array of disciplines.

Dr. Hoppin brings 20 years of experience in the medical imaging research community to inviCRO, which has been included on IncMagazine’s 500|5000 list of fastest-growing privately owned US companies for two consecutive years.

Before co-founding inviCROin 2008, Dr. Hoppin served as the VP of Imaging Systems at Bioscan, Inc., worked as an Alexander von Humboldt post-doctoral fellow at the ForschungszentrumJülich, Germany, and received his PhD in applied mathematics in 2003 from the University of Arizona.

Dr. Hoppin sits on multiple boards and committees including the Board of Trustees for the World Molecular Imaging Society.